2017
DOI: 10.1016/j.bmcl.2017.04.036
|View full text |Cite
|
Sign up to set email alerts
|

Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
18
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 16 publications
(18 citation statements)
references
References 22 publications
0
18
0
Order By: Relevance
“…Other studies have demonstrated their therapeutic effects on obesity, neuropathy, and hepatic and renal pathologies. Recent studies have also shown that it is possible to design DPP‐IV inhibitors with dual bioactivity on other targets involved in cardiovascular diseases like ACE or β‐adrenergic receptors …”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations
“…Other studies have demonstrated their therapeutic effects on obesity, neuropathy, and hepatic and renal pathologies. Recent studies have also shown that it is possible to design DPP‐IV inhibitors with dual bioactivity on other targets involved in cardiovascular diseases like ACE or β‐adrenergic receptors …”
Section: Introductionmentioning
confidence: 99%
“…Virtual screening (VS) has been used over recent years to discover DPP‐IV inhibitors in molecular databases, with most of the inhibitors identified having bioactivity in the μM range (see Table , but with no measurement of their selectivity over related enzymes like DPP8 and DPP9 (inhibition of either DPP8 or DPP9 has been suggested as responsible for alopecia, thrombocytopenia, reticulocytopenia, multiorgan histopathological changes, enlarged spleen, and mortality in rats and gastrointestinal toxicity in dogs, while DPP9 inhibition produces neonatal lethality in mice) . In contrast, several recent structure–activity studies (SAR) in the literature describe the synthesis of novel and selective compounds with nM activity as DPP‐IV inhibitors …”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…The results demonstrated that long-term treatment with teneligliptin significantly improved endothelial dysfunction and glucose metabolism in a rat model of metabolic syndrome suggesting that teneligliptin treatment might be beneficial for patients with hypertension and/ or diabetes [33]. Recently Sattigeri et al developed chimeric DPP4/ angiotensin-converting enzyme inhibitors for treating metabolic syndrome by rational de novo synthesis exhibiting polypharmacology to address multifactorial diseases (hyperglycemia, hypertension, and dyslipidemia) [4].…”
Section: Dpp4 Inhibitors In the Management Of Hyperlipidemiamentioning
confidence: 99%
“…Identifying drug candidates exhibiting polypharmacology could be one of the strategies beneficial to address multifactorial diseases as indicated in Table 1. As a consequence, availability of a single therapeutic agent which would simultaneously ameliorate the pharmacological processes contributing to multifactorial diseases could be a significant step forward in the treatment of metabolic syndrome [4].…”
Section: Introductionmentioning
confidence: 99%